Neumora Therapeutics, Inc. Common StockNMRANASDAQ

Revenue (LTM)

Net Income (LTM)

$-244M

-3.3% YoY

Free Cash Flow

$-183M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	0	0	0	0	0
Gross Profit	0	0	0	-1	0
Operating Income	-96	-237↓148.5%	-136↑42.7%	-188↓38.5%	-263↓40.0%
Net Income	-99	-237↓139.1%	-131↑44.8%	-236↓80.2%	-244↓3.3%
EBITDA	-95	-237↓148.2%	-135↑42.9%	-188↓38.6%	-263↓40.2%
EPS Diluted	-0.65	-1.56↓140.0%	-0.86↑44.9%	-1.49↓73.3%	-1.53↓2.7%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	192	409↑113.2%	241↓41.1%	374↑55.2%	142↓62.0%
Total Current Assets	194	416↑114.4%	388↓6.7%	478↑23.3%	314↓34.3%
Total Assets	198	429↑116.9%	426↓0.7%	496↑16.4%	317↓36.1%
Total Current Liabilities	9	23↑148.4%	24↑1.8%	25↑6.0%	30↑19.0%
Total Liabilities	292	755↑158.1%	873↑15.7%	27↓96.9%	30↑10.3%
Total Equity	-94	-325↓244.6%	-447↓37.4%	469↑205.0%	287↓38.8%
Total Debt	2	2↑0.3%	8↑311.4%	5↓38.0%	2↓64.6%
Net Debt	-190	-407↓114.4%	-233↑42.9%	-369↓58.6%	-140↑62.0%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-27	-75↓181.8%	-115↓52.3%	-163↓42.1%	-183↓12.0%
Capital Expenditure	-1	-1↑37.2%	-1↑37.5%	-0↑77.1%	0
Free Cash Flow	-28	-76↓171.7%	-115↓51.4%	-163↓41.6%	-183↓12.0%
Stock-Based Comp	2	4↑155.2%	8↑94.2%	17↑107.8%	40↑132.0%
Net Change in Cash	192	217↑13.1%	-167↓176.9%	133↑179.6%	-232↓274.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance